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Airway diseases are highly prevalent worldwide; however, the prevalence of these diseases is underestimated.
Although these diseases present several common characteristics, they have different clinical outcomes. The
differentiation between asthma, chronic obstructive pulmonary disease and bronchiectasis in the early stage of
disease is extremely important for the adoption of appropriate therapeutic measures. However, because of the high
prevalence of these diseases and the common pathophysiological pathways, some patients with different diseases
may present with similar symptoms. The objective of this review is to highlight the similarities and differences
between these diseases in terms of the risk factors, pathophysiology, symptoms, diagnosis and treatment.
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INTRODUCTION
The prevalence of airway diseases has increased in recent
decades despite therapeutic advances. Furthermore, the
prevalence of these diseases is underestimated according to
epidemiological surveys, which further increases the com-
plexity of managing these diseases. In Brazil, acute asthma
exacerbations and chronic obstructive pulmonary disease
(COPD) are major causes of hospitalization (1,2). Despite the
presentation of similar symptoms, such as dyspnea, cough-
ing, wheezing and expectoration, airway diseases have
different underlying pathophysiological processes and must
be distinguished to enable the administration of appropriate
treatment. With an appropriate clinical history and objective
diagnostic testing, the distinction between these diseases
can be performed efficiently in most cases. However, many
patients who are evaluated for respiratory symptoms are
misdiagnosed due to an atypical case presentation, an
insufficient etiological investigation or an overlapping of the
diseases.
This review aims to present the similarities and differ-
ences between airway diseases and suggest a practical
approach for the differentiation of the most common
respiratory illnesses, i.e., asthma, COPD and bronchiectasis.
Epidemiology
Because of the variability in the definition of COPD in
epidemiological studies, an accurate prevalence of this disease
is difficult to determine. The prevalence is approximately 14%
in smokers, 7% in former smokers and 3% in individuals
who never smoked (3). Surveys on the prevalence of asthma
suggest a prevalence of approximately 9% in the British
population. In Brazil, an epidemiological study of the
population in Sa˜o Paulo revealed a COPD prevalence of
15.8% (4), whereas the prevalence of asthma was estimated
to be approximately 10% of the general population (1).
Several studies have suggested a similar prevalence of
asthma among children and adult populations; however,
extensive variability has been found depending on multiple
factors that include geographic differences and socioeco-
nomic status (5).
Because of a lack of well-conducted epidemiological
studies, an accurate prevalence of bronchiectasis is more
difficult to estimate than that of asthma and COPD. There
has been a decrease in the incidence of this disease, which
has been attributed to the increased use of antibiotics for
infection control and immunization strategies in children.
Tsang and Tipo (6) reported a hospital admission rate of
16.4 per 100,000 people and a mortality rate of 1 out of
100,000 people in Hong Kong.
The overlap in the terminology that is used to define
asthma, chronic bronchitis, emphysema, COPD and bronch-
iectasis is the greatest cause of confusion in distinguishing
these diseases and in accurately determining the prevalence
of airway diseases. The prevalence of obstructive diseases in
adults can vary by more than 200% in the general
population and depends on the definition that is used (a
self-reported diagnosis versus a diagnosis based on spiro-
metry findings) (7). Furthermore, the actual prevalence of
obstructive diseases is underestimated. When a spirometric
evaluation was performed in the general population,
approximately 58% of the patients with an obstructive
disorder did not report a prior lung disease diagnosis (8).
Individual patients may have different combinations of
airway diseases. Studies in an American population
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demonstrated that more than 15% of the patients with an
obstructive disease received more than one diagnosis, and
this rate reached 50% in a population older than 50 years of
age (8). In Australia (9), this proportion was approximately
25% in individuals who were between 45 and 69 years of
age. In Italy (10), approximately 20% of the asthmatic
population had symptoms that included a productive
cough, which is compatible with a diagnosis of chronic
bronchitis. Patients who exhibit the coexistence of two or
more obstructive diseases tend to be older and have
spirometric data that indicate lower values of forced
expiratory volume in the first second (FEV1) (8).
Furthermore, the coexistence of asthma and COPD was
associated with a higher mortality rate (11).
The high prevalence and morbidity of these diseases
translates into a substantial cost to the healthcare system.
Drug costs are the main expenses that are associated with
the treatment of asthma, whereas COPD and bronchiectasis
have a greater economic impact due to high hospitalization
rates (12). The main findings from these epidemiological
studies are as follows: (1) the prevalence of chronic
obstructive pulmonary disease, which is closely correlated
with the definition that is used, is an important social and
economic problem; (2) the overlap between asthma, COPD
and bronchiectasis is associated with an increase in clinical
severity and mortality; and (3) approximately half of
patients with obstructive findings on spirometry are not
properly diagnosed; therefore, screening programs that
include a pulmonary function evaluation (with an assess-
ment of both spirometry and peak flow) should be adopted
to decrease the proportion of patients without adequate
monitoring (13,14).
Risk factors
Patients with asthma and COPD can usually be distin-
guished according to the classic risk factors that are
associated with each disease. However, certain risk factors
may be common in both diseases. Regarding the illnesses
that are associated with bronchiectasis, the identification of
the risk factors is crucial and is complex because of the wide
variety of conditions that predispose a patient to a
permanent dilation of the airways (15) (Table 1).
In atopic individuals, the main risk factor for developing
asthma is exposure to allergens. Consequently, many
patients with asthma have high serum levels of IgE and
eosinophils (16,17). For individuals with non-atopic asthma,
several risk factors have been found, including smoking,
occupational exposure, advanced age, an unfavorable socio-
economic condition and housing in an urban center (18).
Asthma can be induced by either animal or plant proteins
and by organic and inorganic chemical agents (19,20). In
addition, the development of asthma is correlated with the
Western lifestyle, which is characterized by a high hygiene
rate. Increased hygiene reduces exposure to allergens and
decreases natural desensitization (21). The exposure to
external agents can result in the development of COPD,
which is mainly associated with occupational activities,
such as coal and gold mining (22), cadmium mining (23)
and exposure to smoke from burning wood (24,25).
Regarding bronchiectasis, exposure to fungi is a cause of
exacerbated allergic responses, such as in allergic bronch-
opulmonary aspergillosis (15).
Smoking is the main etiological factor for the develop-
ment of COPD. While it is known that quitting smoking is
the only factor that can slow the progression of this disease,
there is no evidence that there exists a reversion for
the pulmonary impairment that has already began.
Approximately 90% of COPD cases are related to smoking,
whereas other less common risk factors include occupa-
tional exposure and biomass burning (26,27,28). The
historical finding of a lower prevalence of COPD in the
female population is associated with a lower proportion of
smokers in this group. However, an increase in the number
of women who smoke in recent decades has increased the
prevalence of COPD in the female population and the
mortality that is associated with this pathology (29-31).
In Brazil, data indicate a decline in the smoking
prevalence (32); however, several factors are extremely
relevant. There are an insufficient number of effective public
policies that discourage smoking among young people who
are usually influenced by alcohol consumption, media
advertising and paternal smoking (33). In addition, a large
portion of pneumologists in Brazil need to be trained
because these physicians cannot effectively treat smoking
(34). These steps are crucial in reducing the prevalence of
COPD.
Regarding genetic factors, several conditions are classi-
cally associated with the development of COPD. A
deficiency of alpha-1 antitrypsin decreases the defense of
the lungs against inhaled noxious agents, thus increasing
the development of emphysema. Patients with this defi-
ciency account for approximately 1-2% of COPD cases
Table 1 - Risk factors for asthma, COPD and bronchiectasis.
Asthma COPD Bronchiectasis
Environmental factors Allergen exposure Smoking Respiratory infections
Occupational sensitizers Occupational exposure Bronchial obstructions
Respiratory infections Pollution Transplantation
Alcoholism
Low socio-economic condition
Host factors Atopy Alpha-1 antitrypsin deficiency Alpha-1 antitrypsin deficiency
Gender Low birth weight Cystic fibrosis
Low birth weight Family history Immunodeficiency
Genetic predisposition Autoimmune disease
Mucociliary dysfunction
Yellow nail syndrome
Congenital diseases (Mounier-Kuhn syndrome,
Williams-Campbell syndrome)
COPD: Chronic obstructive pulmonary disease.
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(35,36). Other genetic influences on the development of
COPD include a polymorphism in the promoter region of
inflammatory mediators, such as tumor necrosis factor-
alpha (TNF-alpha) (37), and polymorphic variants in the
hydrolase-encoding genes (38).
Several genetic diseases are associated with the develop-
ment of bronchiectasis. Cystic fibrosis is characterized by a
mutation in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene and is the leading cause of genetic
disease-related death among Caucasians, which is typically
due to respiratory failure. In addition, immotile cilia
syndrome (primary ciliary dyskinesia) and genetic anoma-
lies that are associated with a humoral or cellular
immunodeficiency are common causes of bronchiectasis
(39).
Several studies have analyzed the development of asthma
and specific genetic alterations but have not found an
association. Because of the multifactorial presentation of this
disease, the existence of a single genetic site associated with
the development of this disease is questionable. However,
evidence suggests that chromosomal regions may modulate
the degree of disease severity, such as the relationship
between chromosome 2q and the levels of IgE and bronchial
hyperresponsiveness (40).
The influence of gender on the development of asthma
varies with age. Childhood asthma is more common among
boys, whereas women are more commonly diagnosed with
asthma in adulthood (41,42). COPD is more common among
men than women, which is related to the gender difference
in smoking intensities (43). However, women develop more
severe airflow obstruction than men after an adjustment for
the tobacco intake intensity (44,45).
Additionally, other factors influence obstructive respira-
tory diseases. The presence of gastroesophageal reflux is
correlated with increased inflammation in the airways of
patients with bronchiectasis and is associated with
increased asthma severity. However, because of a lack of
well-conducted longitudinal studies, the relationship
between gastroesophageal reflux disease and bronchial
hyperresponsiveness may not be causal and may not be
associated with severity (46). In addition, a low birth weight
may predispose individuals to the development of asthma
(47) or COPD (48). The proposed mechanism for this
association is based on the normal respiratory functional
decline with age that occurs from a lower peak in these
individuals. Additionally, a history of viral or bacterial
infections in childhood is correlated with the development
of asthma, and these infections are well-established causes
of bronchiectasis in adulthood (49,50). Passive smoking and
a deficiency of certain dietary elements, such as polyunsa-
turated fatty acids, are associated with the development of
chronic airway inflammation in adulthood (51).
Physiopathology
Asthma, COPD and bronchiectasis are diseases that cause
chronic inflammation of the airways but have distinct
characteristics. In asthma, eosinophils, mast cells and CD4
T lymphocytes represent the predominant cell types in the
inflammatory process. In contrast, COPD and bronchiectasis
demonstrate a greater number of neutrophils, macrophages
and CD8 T lymphocytes (52-54).
Asthmatic patients have airway obstructions that are
predominantly characterized by bronchoconstriction
through the activation of the smooth muscle and basal
membrane thickening. These alterations are positively
correlated with the frequency of asthma attacks and
bronchial hyperresponsiveness (55,56).
COPD patients exhibit a reduced airway caliber, which is
associated with cell damage that is induced by external toxic
agents, especially cigarette smoke, via reactive oxygen
species (57,58). The presence of goblet cells (mucous
metaplasia) in the small airways and mucous hypersecre-
tions results from the process of airway narrowing (59,60).
Despite the prevalence of inflammation in COPD, which
occurs due to the presence of neutrophils and macrophages,
several studies have demonstrated the presence of eosino-
philic inflammation both in stable patients and in patients
with acute exacerbations of the disease (61). This finding
confirms the potential anti-inflammatory effect of inhaled
corticosteroids in the treatment of COPD. Another interest-
ing finding for this disease is the correlation between
inflammation intensity and COPD severity. In the final
stages of the disease, an intense inflammatory process
occurs, which suggests that, even in these scenarios,
treatment with anti-inflammatory drugs, such as inhaled
corticosteroids, may be effective (62).
Bronchiectasis develops with recurrent damage to the
airways, which generally occurs in individuals with
mucociliary clearance that is altered by genetic suscept-
ibility, thus leading to inflammation and destruction of the
muscular and elastic components of the bronchial walls (63).
Respiratory infections are the leading causes of bronchiec-
tasis; however, other pro-inflammatory attacks can trigger
or accelerate the process, such as a toxin inhalation,
environmental exposure, smoking, aspiration of gastric
contents or changes in immune responses (6).
Abnormally dilated airways are susceptible to bacterial
colonization, which leads to a constant presence of
inflammation that is mainly mediated by neutrophils (64).
There is progressive impairment of ciliary function with a
worsening of airway mucociliary clearance, which further
facilitates the presence of bacterial colonization and the
accumulation of thick mucus (65,66). In addition, the
perpetuation of inflammation leads to further damage to
the mucosal integrity of the airways, thus promoting
continuous bacterial invasion and permanence in the
mucosa. This infectious and inflammatory cyclic process
causes progressive damage to the bronchial wall with
associated clinical deterioration. Increased arterial bronchial
proliferation and arteriovenous malformations can occur as
a result of the inflammatory process and bronchial wall
alterations. This vicious cycle can produce significant
bacterial proliferation and inflammation with increased
suppuration and clinical worsening.
However, understanding the inflammatory patterns of
each disease is important for distinguishing between airway
diseases. In a study of 27 COPD patients and 19 asthma
patients with similar degrees of pulmonary obstruction,
several parameters were evaluated. Several functional
(residual volume and diffusion capacity) and tomographical
(emphysema score) parameters could differentiate between
the individuals with COPD and those with asthma.
However, the inflammatory and pathological features of
basal membrane thickening, eosinophilia and the CD4/CD8
relationship in the bronchoalveolar lavages were the best
predictors of a history of asthma (67).
Immunological differentiation may have an impor-
tant prognostic role in patients. Sputum eosinophilia is
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associated with difficult-to-control asthma (68), and the
normalization of this condition after treatment was corre-
lated with a decrease in the number of exacerbations and
hospitalizations. Neutrophilic inflammation in asthma is
less sensitive to corticosteroid treatment and is associated
with rapid functional loss (69).
Despite the distinct pathophysiological mechanisms of
airway diseases, these diseases share several common
features. Specific therapies, especially anti-inflammatory
medications and bronchodilators, may be the most bene-
ficial treatments for these diseases because these drugs
control symptoms and improve the quality of life of the
patients.
Diagnosis
Characterizing the physiological and phenotypic differ-
ences between patients with obstructive diseases is impor-
tant for obtaining a greater understanding of the evolution
of these diseases and the therapeutic implications. Most
patients can be distinguished by a detailed clinical history
and simple functional and imaging tests; however, many
patients have atypical clinical profiles due to the hetero-
geneity of the airway diseases, which can lead to a
misdiagnosis. This factor is particularly important for the
elderly population in which the coexistence of asthma,
COPD and bronchiectasis is common.
Symptoms
Asthmatic patients who exhibit bronchoconstriction are
characterized by wheezing, breathlessness, chest tightness
and coughing. The characteristic of the reversible inflam-
matory process in asthma and a good response to
therapeutic measures characterize the evolution of the
disease, which is marked by intermittent exacerbations
(70-72). However, the lack of these symptoms can define a
subgroup of patients who are considered hypoperceivers
and who evolve with a worse prognosis for disease control
(73).
The main clinical manifestation of patients with bronch-
iectasis is a chronic cough with sputum production,
although patients may only have a dry cough. Patients
often have dyspnea on exertion (75%), wheezing (75%) and
pleuritic chest pain (50%). Additionally, patients may have
systemic symptoms, such as fatigue or weight loss, and
rhinosinusitis. A physical examination may identify crackles
(70%), snoring (44%) and wheezing (34%). Clubbing
appears in approximately 3% of the cases. The clinical
evolution consists of a progressive functional loss and is
marked by recurrent infectious exacerbations with the need
for frequent antibiotics (15).
Patients with COPD have a cough that is frequently
associated with chronic sputum production (74). Cha-
racteristically, these individuals present with dyspnea and
effort limitations due to the fixed airflow obstruction (75-
77). More advanced stages of the disease result in a worse
quality of life for these patients. Respiratory exacerbations
are associated with an increased underlying inflammatory
process that requires appropriate therapy with antibiotics
and systemic corticosteroids. These exacerbations are
characterized by a worsening of the basal symptoms of
the patient, such as cough, expectoration and dyspnea.
According to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD), an exacerbation is defined as ‘‘an
event in the natural course of the disease characterized by a
change in dyspnea, cough and/or basal expectoration of the
patient who goes beyond the normal daily variation, and
that can cause a change in regular medication of the
patient’’ (78).
Lung function
In asthma, the typical finding of airflow obstruction that
is characterized by a decrease of VEF1/FVC (forced vital
capacity) with a disorder reversal after the administration of
a bronchodilator is the mainstay in the diagnostic confirma-
tion of the disease (79). However, many patients may
present with a reversal after the use of a bronchodilator
without exhibiting normalization in pulmonary function
tests, thus indicating signs of bronchial remodeling. In
addition, clinically stable patients may present with normal
spirometry but a positive bronchial provocation test (1).
Other functional variables can be used for the diagnosis of
obstructive lung disease, such as the forced expiratory flow
at 50% of the FVC FEF50%/0.5FVC (80) ratio. However, the
use of the FEV1/FVC ratio remains the most widely
accepted parameter for diagnostic confirmation.
In COPD, a post-bronchodilator FEV1,80% that is
associated with a FEV1/FVC ratio ,70% confirms the
obstructive disorder, which is characterized by a lack of
complete reversibility of airflow. However, a significant
response to the bronchodilator does not exclude a COPD
diagnosis (78).
More accurate functional tests can differentiate between
these two diseases through measures that assess lung
hyperinflation and the diffusion capacity of the lungs for
carbon monoxide (DLCO). Hyperinflation, which is con-
firmed by plethysmography, is more commonly found in
COPD that is characterized by a greater residual volume
than is found in asthma. Another characteristic of COPD is a
decrease in the DLCO (70).
Early in the course of the disease, patients with
bronchiectasis usually present with lung function tests that
are characteristic of an obstructive disorder, thus confirming
the inflammatory nature of this disease and the initial
involvement of the small airways. However, with the
progression of the disease, a mixed functional disorder or
a restrictive disorder can be found due to the progressive
destruction of the pulmonary parenchyma, which is
characterized by recurrent infectious exacerbations and
massive destruction of the small airways (81).
Imaging tests
Chest radiography is not sufficiently sensitive for the
diagnosis of airway diseases, and this test is recommended
for the differential diagnosis of a patient with respiratory
symptoms. In more severe cases of patients with bronch-
iectasis, the dilation of large airways can be visualized as a
thickening of the peribronchovascular interstitium using
this method. A universal radiographic finding in obstructive
diseases is lung hyperinflation, which is characterized as
follows: (1) an increase in the lung volume, (2) an increase in
the intercostal spaces, (3) a rectification of the diaphragmatic
domes, (4) an accentuation of the retrosternal space and (5)
the presence of air below the inferior border of the heart
(82).
A thoracic CT scan is a more sensitive test than chest
radiography and is useful in the management of airway
diseases. This test is considered the gold standard in the
diagnosis of bronchiectasis. Common findings in obstructive
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diseases include bronchial wall thickening, centrilobular
nodules and mosaic attenuation by air trapping (82).
The following tomographic criteria are used for the
diagnosis of CT bronchiectasis: (1) a bronchial internal
diameter that is larger than 1.5 times the diameter of the
adjacent pulmonary artery (signet ring sign), (2) an absence
of a gradual decrease in the bronchial diameter from the
central regions to the periphery and (3) bronchial visualiza-
tion in the periphery 1-2 cm from the parietal pleura (6).
According to CT scan findings, we can classify bronchiec-
tasis as cylindrical (bronchial dilation), varicose (with focal
constrictions along the airways) or cystic (saccular dilations
at the end of a bronchus). In addition, we can classify the
bronchiectasis as localized (i.e., confined to one lobe) or
generalized (83).
In asthma patients, bronchial wall thickening and air
trapping are commonly found; however, patients with mild
asthma may have completely normal thoracic tomography
findings. However, current analyses with quantitative
techniques and high-resolution scans can distinguish
between normal and mildly controlled asthmatic individuals
based on the degree of air trapping and bronchial thickening.
Moreover, severe asthma is associated with a greater degree
of bronchial thickening in these individuals. Another inter-
esting finding of these studies is that a greater degree of air
trapping was associated with an increased risk of exacerba-
tion. Because CT scan is noninvasive, this technique may be
used to monitor patients with severe asthma, especially for
the evaluation of bronchial remodeling (84,85).
In patients with COPD, the most important tomographic
finding is the presence of centrilobular emphysema in the
superior lung fields (smoking-related) or diffuse panlobular
emphysema (alpha-1 antitrypsin deficiency). The intensity
of emphysema, which is characterized by the amount of
area with low attenuation, and bronchial thickening
correlate with the degree of airflow obstruction that is
measured in functional tests (86-88).
Therefore, thoracic tomography is an important tool that
can be used in the differential diagnosis of airway diseases
(Figure 1). However, many of these CT findings are
common among several obstructive diseases, and more
advanced stages of asthma and COPD may lead to the
development of bronchiectasis.
The diagnosis of an airway disease in patients should
begin with a detailed anamnesis, and complementary exams
should be performed as appropriate. No single test can
completely differentiate between these diseases. The coex-
istence of more than one disease in the same patient should
always be considered when a patient presents with an
unfavorable clinical evolution or when their laboratory tests
are not consistent with the initial clinical hypothesis
(Table 2).
Treatment
Asthma treatment guidelines aim for the appropriate
control of symptoms through a strategy of phased measures
that focus on the severity of the disease and the daily
complaints of the patient. Once this goal has been achieved,
the treatment should be maintained at the lowest possible
dosage to reduce side effects and the associated costs (1,5).
In addition, the guidelines for the treatment of COPD use a
phased strategy according to the severity of the disease.
However, the guidelines emphasize the prevention of
disease progression. Moreover, once the treatment goal
has been achieved, a reduction in the medication dosage is
uncommon (2,78,89). Regarding bronchiectasis, there is a
lack of literature on the guidelines for the treatment of this
pathology. British guidelines were recently published (90);
however, there are few data on the therapeutic recommen-
dations for bronchiectasis due to a lack of well-conducted
randomized clinical trials. Many measures are still being
extrapolated from studies of cystic fibrosis, but physicians
must be aware of the differences between the various
diseases that may be similar to bronchiectasis (91).
Much of the therapeutic arsenal is common between
obstructive diseases, especially bronchodilators (beta2-ago-
nists and anticholinergics) and inhaled corticosteroids.
However, the treatment goal for each disease may vary.
COPD therapy is directed primarily to the relief of
symptoms and the prevention of disease progression. In
bronchiectasis, the primary goal of treatment is to prevent
disease progression and improve the quality of life and
symptoms. In asthma, the primary goal of treatment is to
control the underlying inflammatory process with the
consequent control of symptoms.
Beta2-agonists
Bronchodilators with a direct action on beta-adrenergic
receptors can be classified as short- or long-term depending
on the half-life.
Short-acting beta2-agonists (SABAs) are the first-line
treatment for COPD; however, the use of SABAs as a rescue
medication in asthma is appropriate. In patients with
bronchiectasis, SABAs are generally used for symptom
relief despite the lack of evidence for the use of these drugs.
In contrast, long-acting beta2-agonists (LABAs) are used
in combination with anti-inflammatory medications in
asthma. LABAs may be used alone in patients with
COPD. The isolated use of a beta2-agonist in asthma is
contraindicated and is associated with a poor prognosis (92).
Figure 1 - Tomographic cross-sections. A) Asthmatic patient with diffuse bronchial wall thickening. B) COPD patient with extensive
areas of centrilobular emphysema predominantly in the superior lung fields. C) Patient with cystic and varicose bronchiectasis
characterized by dilation and thickening of airways.
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These drugs act by relaxing the bronchial smooth muscle,
increasing the mucociliary clearance, decreasing the vascu-
lar permeability and possibly reducing inflammatory
mediators (5).
In COPD, the use of LABAs is associated with functional
improvement (increased FEV1), symptom control and
improved quality of life (93,94). In asthmatic patients, the
combination therapy of a LABA with inhaled corticosteroids
(ICs) is more efficient in controlling symptoms than an isolated
increase in the IC dosage (95). For patients with bronchiectasis,
the combination of a LABA with a conventional IC improved
the symptom scores and quality of life (96).
Anticholinergics
The release of acetylcholine by vagal stimulation triggers
a bronchoconstrictor response and an increased production
of pulmonary secretions. The use of short-acting antic-
holinergic drugs (ipratropium) in patients with COPD
yielded a dose-dependent functional improvement with
better responses than those that were achieved using a
SABA. For asthma, ipratropium is usually only used for the
management of severe asthma attacks, and there is no
evidence of benefits in patients with bronchiectasis (97).
Long-acting anticholinergics (LAMAs) have a prolonged
half-life (36 hours) with an action peak of approximately 1-2
hours (98). Tiotropium is the most studied pharmacological
agent, and COPD studies have indicated satisfactory results,
including a reduction in the number of exacerbations, an
improvement in quality of life and an increase in the FEV1
(99). There is no evidence that supports the superiority of
LAMAs over LABAs; however, the combination of these
drugs may be used with an additive effect in patients with
accentuated lung function or significant functional limita-
tions (100). Recently, the use of tiotropium in asthma has
been studied as an alternative in patients with contra-
indications to the use or in combination with LABAs (101).
Similar to ipratropium, the use of tiotropium for the
treatment of bronchiectasis has not been adequately studied.
Corticosteroids
The underlying inflammatory process in obstructive
diseases has always been the focus of therapeutic interven-
tions that aim to reduce disease progression, improve lung
function and reduce symptoms and exacerbations. In
asthma, inhaled corticosteroids are the mainstay of disease
treatment and are considered the first-line treatment in
patients with persistent asthma. ICs can reduce the number
of exacerbations, improve lung function and quality of life,
control respiratory symptoms and decrease the bronchial
hyperresponsiveness (102-104). Current guidelines empha-
size the use of an IC in the initial therapy of patients with
asthma symptoms. The combination of an IC with a LABA
is recommended as the next step in therapy despite the
potential need to increase the IC dosage (1,5). However, the
use of measures that increase patient adherence to treatment
and the adequate use of inhalers are fundamental to
achieving good clinical control of symptoms (105-108).
The use of an IC to treat COPD was effective in reducing
airway inflammation, although the IC did not affect the rate
of functional decline. There are conflicting data on the
ability of an IC to improve lung function, whereas there are
concrete data that associate the use of an IC with a
significant reduction in the exacerbation rate of COPD and
improvements in the quality of life of COPD patients (109).
The discontinuation of treatment results in a poor quality of
life and a faster exacerbation recurrence (110). Current
guidelines recommend the use of an IC in patients with
advanced pulmonary disease that is characterized by a
severe obstructive disorder or a large number of exacerba-
tions (78).
In patients with bronchiectasis, the use of an IC was
effective in reducing the inflammatory markers and sputum
volume. The amount of daily sputum in patients with
bronchiectasis is an important severity marker that corre-
lates with the number of lung exacerbations. However,
studies have not demonstrated a significant impact of ICs on
the lung function and exacerbation rate in individuals with
bronchiectasis (111).
Other pharmacological agents
Xanthines, such as theophylline, have moderate bronch-
odilator effects, immunomodulatory properties and anti-
inflammatory effects, which increase sensitivity to corticoids
in the nucleus of inflammatory cells through the histone
deacetylase pathway. However, the clinical effects of
xanthines, which are associated with a reduced therapeutic
range and an increased risk of severe side effects, have
reduced the clinical applicability of these drugs. The use of
Table 2 - Important clinical characteristics in the differentiation of patients with asthma, COPD and bronchiectasis.
Clinical characteristic Asthma COPD Bronchiectasis Potential overlap
Risk factors Family history Allergies Smoking Repeated infections
Immunodeficiency
Asthmatics Smokers have an
increased risk of developing COPD
Age Children and young people Advanced age Variable Asthma and bronchiectasis are
misdiagnosed in the elderly and
are commonly mistaken for COPD
Symptoms Wheezing Outbreaks of
dyspnea
Chronic dyspnea
Productive cough
Productive cough Patients with bronchiectasis are
diagnosed late because they are
first treated for COPD due to
productive cough symptoms
Spirometry Reversibility Absence of reversibility Absence of reversibility
May present restrictive pattern
Asthmatic patients may lose
reversibility over time
Computerized tomography Bronchial thickening Central lobular
emphysema
Bronchial dilations Bronchial thickening can occur in
patients with COPD and
bronchiectasis, and bronchiectasis
may appear in asthmatics and
individuals with COPD
COPD: Chronic obstructive pulmonary disease.
Differentiating airway diseases
Athanazio R
CLINICS 2012;67(11):1335-1343
1340
xanthines is increasingly reserved for severe cases, espe-
cially in patients with COPD (78).
Anti-leukotrienes, such as montelukasts, can reduce
eosinophilic inflammation through inhibition of the lipox-
ygenase pathway. The bronchodilator effect of anti-leuko-
trienes is discrete, and the use of these drugs is reserved for
asthmatic patients; however, there is no concrete clinical
applicability of these drugs in COPD (5).
Other nonpharmacological therapies
Nonpharmacological measures are important in the
management of patients with an obstructive disease.
Smoking cessation in patients with COPD or who are at
risk for the development of COPD (such as individuals with
asthma) must be encouraged. Although lung damage can
continue to progress, smoking cessation was effective in
reducing the rate of lung function decline (112).
Viral infections are a major cause of exacerbations in
patients with asthma, COPD and bronchiectasis and are
associated with a higher mortality rate. Vaccination against
influenza is demonstrably linked to a reduction in severe
exacerbations and mortality. Therefore, all patients with an
obstructive disease should be directed to receive an annual
flu shot. Conversely, the efficacy of the pneumococcal
vaccine is not yet fully understood. Patients with a
respiratory disease are at an increased risk of hospitalization
for pneumonia, especially the elderly; therefore, the use of
this vaccine should be considered (5,78).
The use of bronchial thermoplasty has been considered an
option in patients with severe asthma. Studies in indivi-
duals with severe persistent asthma demonstrated a reduc-
tion in the exacerbation rate and an improvement in
symptom control. The finding of hypertrophied smooth
bronchial muscles in asthma patients justifies the use of this
approach. The use of a probe by bronchoscopy that releases
heat into the airway and leads to the destruction and/or
atrophy of bronchial smooth muscle supports the biological
plausibility for the use of this technique (113,114).
Pulmonary rehabilitation and an increase in physical
activity interventions are useful for the improvement of
respiratory symptoms and fitness. These measures are
effective in the treatment of COPD patients (115). In addition,
data in the literature suggest that asthma and bronchiectasis
patients may benefit from these measures (116).
The prevalence of obstructive diseases continues to
increase worldwide, with a considerable social and eco-
nomic impact. Understanding the pathophysiological pro-
cesses that underlie the various diseases that cause airflow
limitations is essential for differentiating between these
diseases. Therefore, specific diagnostic methods can be
used, and adequate therapeutic interventions can be
applied. However, the possibility that more than one
condition coexists in the same patient should not be
underestimated, especially due to the high prevalence of
these diseases in the elderly population.
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